Ovarian cancer recurrence: “is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?”

PolyADP ribose polymerase inhibitors (PARPi) have transformed the treatment of ovarian cancer. Particularly in high-grade serous ovarian cancer (HGSOC), a disease characterized by homologous recombination deficiency (HRD), PARPi have had a rapid and profound impact on the disease course, as well as...

Descripción completa

Detalles Bibliográficos
Autores principales: Pejovic, Tanja, Fitch, Katherine, Mills, Gordon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2022
Materias:
Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255235/
https://www.ncbi.nlm.nih.gov/pubmed/35800377
http://dx.doi.org/10.20517/cdr.2021.138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255235/
https://www.ncbi.nlm.nih.gov/pubmed/35800377
http://dx.doi.org/10.20517/cdr.2021.138

Ejemplares similares